Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Biktarvy

- PMLiVE

AstraZeneca’s COVID-19 treatment granted EC approval

Evusheld significantly reduced risk of severe COVID-19 or death in a phase 3 trial

- PMLiVE

Otsuka and Aurinia’s Lupkynis granted EC approval as active lupus nephritis treatment

The treatment is for use in combination with mycophenolate mofetil

- PMLiVE

Roche’s Vabysmo receives EC approval to treat two leading causes of vision loss

60% of people treated with Vabysmo were able to extend treatment to every four months

- PMLiVE

Gilead’s Veklury WHO recommendation expanded for treatment of severe COVID-19

The antiviral showed a 17% lower relative risk of death or progression compared to standard of care

- PMLiVE

Novavax’s COVID-19 vaccine candidate receives EC approval for use as a booster

Nuvaxovid induced a ‘robust antibody response’ when used as a heterologous third booster dose

- PMLiVE

Novartis’ Scemblix receives EC approval for chronic myeloid leukaemia

It is estimated that more than 6,300 people will be diagnosed with CML in Europe every year

- PMLiVE

Janssen’s teclistamab granted conditional marketing authorisation by EC

The decision makes teclistamab the first bispecific antibody worldwide to be approved for patients with relapsed and refractory multiple myeloma

- PMLiVE

EC approves Celltrion Healthcare’s Vegzelma for multiple cancer types

The biosimilar to Genentech's Avastin was found to be highly similar to the reference product

- PMLiVE

Gilead Sciences announce positive results for Trodelvy in breast cancer patients

HR+/HER2- breast cancer accounts for around 70% of all new cases, or nearly 400,000 diagnoses worldwide each year

- PMLiVE

Gilead Sciences set to acquire MiroBio in deal worth over $400m

The UK biotech is a spin-out of Oxford University and focuses on research into autoimmune diseases

- PMLiVE

AstraZeneca and MSD’s breast cancer drug Lynparza receives EC approval

Breast cancer is the most diagnosed type of cancer worldwide, with an estimated 2.3 million patients diagnosed in 2020

- PMLiVE

Gilead announces positive Biktarvy data for HIV and hepatitis B

The results were presented at the 24th International AIDS Conference

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links